Loss of EZH2 Reprograms BCAA Metabolism to Drive Leukemic Transformation

Cited by (173)

Items 101–173 of 173

1. Molecular Pathogenesis of BCR-ABL-Negative Atypical Chronic Myeloid Leukemia
   Diletta Fontana, Carlo B Gambacorti-Passerini, Rocco Piazza · 2021 · Frontiers in Oncology
2. CD44-mediated metabolic rewiring is a targetable dependency of IDH-mutant leukemia
   Junhua Lyu, Yuxuan Liu, Ningning Liu, Hieu S. Vu, Feng Cai, Hui Cao, Pranita Kaphle, Zheng Wu, Giovanni A. Botten, Yuannyu Zhang et al. · 2025 · Blood
3. Branched-chain amino acid transaminase 1 inhibition attenuates childhood asthma in mice by effecting airway remodeling and autophagy
   Jing Li, Meixue Chen, Lingling Lu, Jinfeng Wang, Liling Tan · 2022 · Respiratory Physiology & Neurobiology
4. Branched chain amino acids and their aberrant metabolism in cancer
   Morgan L. Brown, Xuanyan Cai, Marie Celeste Simon · 2025 · Trends in cancer
5. Branched-chain amino acids promote occurrence and development of cardiovascular disease dependent on triglyceride metabolism via activation of the mTOR/SREBP-1/betatrophin pathway
   Jie Zhang, Ziyu Liu, Yaojun Ni, Yang Yu, Fei Guo, Yanwen Lu, Xiaoqing Wang, Hairong Hao, Shayan Li, Pan Wei et al. · 2024 · Molecular and Cellular Endocrinology
6. Guanine nucleotide biosynthesis blockade impairs MLL complex formation and sensitizes leukemias to menin inhibition
   Xiangguo E. Shi, Minhua Li, Zian Liu, Jonathan Tiessen, Yuan Li, Jing Zhou, Yudan Zhu, Swetha Mahesula, Ding Qing, Lin Tan et al. · 2025 · Nature Communications
7. The Role of Metabolism in the Development of Personalized Therapies in Acute Myeloid Leukemia
   Vilma Dembitz, Paolo Gallipoli · 2021 · Frontiers in Oncology
8. Metabolic regulation in normal and leukemic stem cells
   Cheuk Him Man, Changzheng Li, Xi Xu, Meng Liang Zhao · 2024 · Trends in Pharmacological Sciences
9. Transcriptomic era of cancers in females: new epigenetic perspectives and therapeutic prospects
   Runhe Zhu, Jiawei Ni, Jiayin Ren, Dongye Li, Jiawei Xu, Xinru Yu, Ying Jie Ma, Luan Kou · 2024 · Frontiers in Oncology
10. DROSHA Regulates Mesenchymal Gene Expression in Wilms Tumor
    Patricia D.B. Tiburcio, Kavita K. Desai, Jiwoong Kim, Qinbo Zhou, Lei Guo, Xue Xiao, Li Zhou, Aysen Yuksel, Daniel Robin Catchpoole, James F. Amatruda et al. · 2024 · Molecular Cancer Research
11. Aberrant BCAT1 expression augments MTOR activity and accelerates disease progression in chronic lymphocytic leukemia
    Qiangqiang Shao, Jedrzej Wykretowicz, Nan Hu, Karan Bedi, Mohamed Rizk, Isabella A. Malek, Surinder Kumar, David B. Lombard, Kerby Shedden, David A. Scott et al. · 2024 · Leukemia
12. Metabolic targeting of malignant tumors: a need for systemic approach
    Aggelos T. Margetis · 2022 · Journal of Cancer Research and Clinical Oncology
13. Deepening Our Understanding of the Factors Affecting Landscape of Myeloproliferative Neoplasms: What Do We Know about Them?
    María Luz Morales, Francisca Ferrer‐Marín · 2023 · Cancers
14. Unveiling the Maze: Branched-Chain Amino Acids Fueling the Dynamics of Cancer Metabolism and Progression
    Kai Xu, Pratham Viral Shah, Dhruvi Makhanasa, Md. Wasim Khan · 2025 · Cancers
15. Multiomic analysis reveals a key BCAT1 role in mTOR activation by B cell receptor and TLR9
    Rui Guo, Yizhe Sun, Matthew Y. Lim, Hardik Shah, João A. Paulo, Rahaman A. Ahmed, Weixing Li, Yuchen Zhang, Haopeng Yang, Liang Wei Wang et al. · 2025 · Journal of Clinical Investigation
16. DDX6 undergoes phase separation to modulate metabolic plasticity and chemoresistance
    Hongjie Bi, Wei Li, Lili Ren, H. Zhang, Lei Dong, Anthony W.H. Chan, Xueer Wang, Lu Yang, Xiaoxu Zhang, Meilin Xue et al. · 2025 · Nature Communications
17. Targeting IGF2BP1 alleviated benzene hematotoxicity by reprogramming BCAA metabolism and fatty acid oxidation
    Jingyu Wang, Han Lin, Ziyan Liu, Wei Zhang, Lei Zhang, Jiaru Jing, Ai Gao · 2024 · Chemico-Biological Interactions
18. Mouse Models of Frequently Mutated Genes in Acute Myeloid Leukemia
    Sagarajit Mohanty, Michael Heuser · 2021 · Cancers
19. Structural classification of EZH2 inhibitors and prospects for the treatment of tumor: a review
    Ling Yu, Ming-tao Xia, Youde Wang, Zhiwei Yan, Liying Zhang, Shuai Li · 2023 · Medicinal Chemistry Research
20. Exploring the action mechanism and effective components of Yupingfeng powder on influenza based on computational system pharmacology and metabolomics
    Ruifeng Chen, Kexin Wang, Luping Lin, Yaorong Chen, Ya Liu, Runfeng Li, Xiao Wu, Pei Feng, Xiaohong Chen, Youhua Xu et al. · 2024 · Journal of Ethnopharmacology
21. Unanchored ubiquitin chain sustains RIG-I-induced interferon-I activation and controls selective gene expression
    Huifang Xian, Wanming Huang, Tingzhe Sun, Shuai Yang, Chuanxia Zhang, Jun Wang, Yuxia Zhang, Jun Cui · 2020 · 中国科学通报：英文版
22. Suppression of UCP2 alleviates leukemogenesis by enhancing branched-chain amino acids-induced oxidative stress via activating the PI3K/AKT/mTOR signaling pathway
    Innocent Okohi Agida, Yajie Shen, Yixuan Gao, Ruixin Sun, Kasimujiang Aximujiang, Zizhen Xu, Jinke Cheng, Jiao Ma · 2025 · Genes & Diseases
23. Astatine-211-Labeled Therapy Targeting Amino Acid Transporters: Overcoming Drug Resistance in Non-Small Cell Lung Cancer
    Sifan Feng, Kentaro Hisada, Haruna Yorifuji, Yoshifumi Shirakami, Kazuko Kaneda‐Nakashima · 2025 · International Journal of Molecular Sciences
24. Compartmentalized branched-chain amino acid metabolism orchestrates colorectal cancer dissemination via an UMP-vimentin axis
    Fenfen Ji, Pingmei Huang, Qiming Zhou, Lok Hin Ko, Qinyao Wei, Charis Cheuk-Lok Chan, D.M. Chen, Huarong Chen, Wei Kang, Alvin Ho-Kwan Cheung et al. · 2026 · Cell Metabolism
25. The Heightened Importance of EZH2 in Cancer Immunotherapy
    Xiaohu Lin, Wenkai Zhou, Chengzhong Lin, Wei Cao · 2023 · Cancer Screening and Prevention
26. BBOX1 mediates metabolic reprogramming driven by hypoxia and participates in the malignant progress of high-grade serous ovarian cancer
    Jiazhen Huang, Ying Chun Tang, Yibing Li, Wei Wei, Fuli Kang, Shuang Tan, Lin Lin, Xiaohang Lu, Heng Wei, Ning Wang · 2024 · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
27. An “EZ” Epigenetic Road to Leukemia Stem Cell Metabolic Reprogramming?
    Meng Li, Ari M. Melnick · 2019 · Cancer Discovery
28. Clinical Significance of Upregulation of EZH1 Expression in Hepatocellular Carcinoma Tissues
    Siyu Chen, Jian‐Di Li, Zhi‐Guang Huang, Rong‐Quan He, Feng Chen, Jianjun Li, Zhaoquan Huang, Ji-Tian Chen, Gang Chen, Yi‐Wu Dang · 2024 · Journal of Gastrointestinal and Liver Diseases
29. PPDPF-mediated regulation of BCAA metabolism enhances mTORC1 activity and drives cholangiocarcinoma progression
    Zhi Li, Yidi Guan, Jie Gao, Lan Zhu, Zimei Zeng, Qianyu Jing, Quan Wan, Qi Fan, Xinxin Ren, Haiping Pei et al. · 2025 · Oncogene
30. Rewiring amino acids in cancer
    Yiqing Zhang, Jianxin Lyu, Hezhi Fang · 2025 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
31. Pathological response and metabolites’ prognostic role in HER2-positive breast cancer treated with neoadjuvant pyrotinib, trastuzumab, nab-paclitaxel, and carboplatin: a single-arm phase II trial
    Mei Liu, La Zou, Ningning Zhang, Wenqi Zhou, Xianjun Pan, Yongchun Deng, Yeli Yue, Jing Wu, Xinrui Liang, Maoshan Chen et al. · 2025 · Breast Cancer Research
32. Metabolism in Hematopoiesis and Its Malignancy
    Xiaoyuan Zeng, Yi-Ping Wang, Cheuk Him Man · 2023 · Advances in experimental medicine and biology
33. Research advances in branched-chain amino acid metabolism in tumors
    Zheng Li, Sainan Chen, Xiaoyan Wu, Fei Liu, Jing Zhu, Jiayi Chen, Xiaojie Lu, Rui Chi · 2024 · Molecular and Cellular Biochemistry
34. Histone modifications in the regulation of erythropoiesis
    Xiuyun Wu, H. Xu, Erxi Xia, Linru Gao, Yan Hou, Lei Sun, Hengchao Zhang, Ying Cheng · 2025 · Annals of Medicine
35. Advances in molecular evaluation of myeloproliferative neoplasms
    Nianyi Li, Mingyi Chen, C. Cameron Yin · 2023 · Seminars in Diagnostic Pathology
36. Insights on the assessment of the potential of phytochemical chelating, protective, and detoxifying properties in managing chronic arsenic toxicity
    Chettri Arati, Rabha Chiranjeeb, Malik Smita Shruti, Chakravarty Dorshon Mimangsha, Gumaa Abdelmuala Abdelgani-Baraka, Lalremruata Andy, Chakma Sonia, Ahmed-Laskar Saeed, Roy Dinata, Vikas Kumar Roy et al. · 2024 · Indian Journal of Biochemistry and Biophysics
37. Dynamics of measurable residual disease for risk stratification and guiding allogeneic transplant in acute myeloid leukaemia patients with myelodysplasia‐related mutations in first remission
    Ling Jiang, Jiaying Cheng, Junya Sun, Yujiao Zhang, Qian Vicky Wu, Yun Huang, Zhiquan Long, Ping Yan, Xuejie Jiang · 2024 · British Journal of Haematology
38. Nonionotropic action of an acid-sensing ion channel inhibits leukemogenesis in the acidic bone marrow niche
    Hao Gu, Lietao Weng, Chiqi Chen, Xiaoxin Hao, Rongkun Tao, Xin Qi, Xiaoyun Lai, Ligen Liu, Tinghua Zhang, Yiming Jiang et al. · 2025 · Journal of Clinical Investigation
39. Distal enhancer RNAs regulate alternative promoter usage of MYB and drug resistance in human leukemia cells
    Yucheng Wang, Xiang Wang, Mengjia Li, Hongkuan Song, Chao Liu, Mengjie Shi, Xiaoxiao Tao, Siyu Shen, Xinyu Li, Huiying Fang et al. · 2026 · Leukemia
40. BCAAs and related metabolic enzymes: partners in crime driving tumor development
    Binfan He, Lingxi Li, Ying Liu, Mengmeng Hao, Ling Zhang, Xinglin Hu · 2026 · Frontiers in Cell and Developmental Biology
41. Metabolic reprogramming drives pancreatic β cell neogenesis from α cells
    Yufeng Zhang, Guangxing Lu, Wenhao Xie, Peng Hui Xu, Cenxi Liu, Oľga Babošová, Jamie Christopher Reilly, Zhehui Li, Leshi Chen, Liying Zhou et al. · 2026 · Nature Chemical Biology
42. Polycomb Repressive Complex 2 in Oncology
    Yiran Guo, Yao Yu, Gang Greg Wang · 2023 · Cancer treatment and research
43. RUNX1::ETO and CBFβ::MYH11 converge on aberrant activation of BCAT1 to confer a therapeutic vulnerability in core‐binding factor‐acute myeloid leukaemia
    Siyang Wang, Yabin Liu, Xujie Zhao, Xiaoling Wang, Jiacheng Lou, Peng Jin, Yi Zhang, Jinyi Yu, Kankan Wang · 2024 · British Journal of Haematology
44. FYN-mediated phosphorylation of BCKDK at Y151 promotes GBM proliferation by increasing the oncogenic metabolite N-acetyl-L-alanine
    Ling Zou, Wei Wang, Wenda Huang, Xiaofang Ni, Wensheng Li, Yue Cheng, Qin Tian, Lin Liu, Feng Zhu, Qiuhong Duan · 2024 · Heliyon
45. Identify BCAT1 plays an oncogenic role and promotes EMT in KIRC via single cell RNA-seq and experiment
    Shiqing Li, Yinsheng Guo, Guanhua Zhu, Lu Sun, Feng Zhou · 2024 · Frontiers in Oncology
46. α-Ketoglutarate promotes amino acid depletion and suppresses B-cell lymphoma growth and development
    Carine Jaafar, Purushoth Ethiraj, Zhijun Qiu, An‐Ping Lin, Pedro S. S. M. Ferrari, Ricardo C.T. Aguiar · 2025 · Blood
47. Multi-omic Analysis of Human B-cell Activation Reveals a Key Lysosomal BCAT1 Role in mTOR Hyperactivation by B-cell receptor and TLR9
    Rui Guo, Matthew Y. Lim, Hardik Shah, João A. Paulo, Yuchen Zhang, Haopeng Yang, Liang Wei Wang, Daniel Strebinger, Nicolas Smith, Meng Li et al. · 2024 · Research Square
48. Association of branched-chain amino acids and risk of three urologic cancers: a Mendelian randomization study
    Haotian Huang, Jiao Qin, Wen Zhi, Chongjian Wang, Caixia Chen, Yang Liu, Hongyuan Li, Song Cao, Xuesong Yang · 2024 · Translational Cancer Research
49. Elucidating the risk factors and oncogene drivers of acute myeloid leukemia
    Daniel Ruben Akiola Sanya, Djamila Onésime · 2025 · Human Cell
50. Branched-chain amino acid transaminases as promising targets in tumor therapy
    Wen Zhang, Jie Shen, Xuanyin Ding, Hele Liu, Xu Wang, Dan Feng · 2026 · Frontiers in Cell and Developmental Biology
51. Mevalonate pathway rewiring driven by enhancer remodelling confers resistance to KRAS inhibitors in colorectal cancer
    Yaoyu Guo, Yi Zhong, Peishan Hu, Yufeng Chen, Wenjun Guo, Jianfeng Chen, Peiyong Guan, Zhengran Zhou, Fang Zhu, Xian Zeng et al. · 2026 · Nature Communications
52. Distinct metabolic dependency on BCAA defines cancer stemness and malignancy in human triple-negative breast cancer
    Kenkyo Matsuura, Ririko Shinonaga, Mizuki Yamamoto, Yoshiki Yamamoto, Hsin Chen, Ayaka Maeno, Kayo Okuda, Haruki Inoue, Sota Imotani, John Glushka et al. · 2026 · Cell Reports
53. Interrogation of Enhancer Function by Enhanced CRISPR Epigenetic Editing
    Kailong Li, Yuxuan Liu, Hui Cao, Yuannyu Zhang, Zhimin Gu, Xin Liu, Andy Yu, Pranita Kaphle, Kathryn E. Dickerson, Min Ni et al. · 2019 · bioRxiv (Cold Spring Harbor Laboratory)
54. Give and take: competition for BCAAs in the tumour microenvironment
    Russell Erick Ericksen, Weiping Han · 2020 · Nature Metabolism
55. EZH2-TTP-mTORC1 Axis Drives Phenotypic Plasticity and Therapeutic Vulnerability in Lethal Prostate Cancer
    Beatriz German, Katherine L. Morel, Teia Noel, Nadia Boufaied, Deborah L. Burkhart, Sujun Chen, Felipe Segato Dezem, Xintao Qiu, Henry W. Long, Stefan DiFazio et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
56. BCAA catabolism mediates POU2AF1 propionylation to enhance T-ALL development
    Junke Zheng, Sijia Dan, Yilu Xu, Xiaoxiao He, Haotian Liu, Lu Zhao, Liyuan Cao, Bo Qu, Yan Lü, Chiqi Chen et al. · 2025 · Research Square
57. DNA damage, metabolism, and epigenetic regulation
    Shinjini Ganguly, Anthony Ghanem, Omar Y. Mian · 2022 · Elsevier eBooks
58. Regulation of Amino Acid Metabolism in Hematological Malignancies: Advances from Transcriptomics and Metabolomics
    Donald Bajia, Gael Noel Neh Neba Ambe, Katarzyna Derwich · 2022 · Journal of Biomedical Research & Environmental Sciences
59. Recent advances in nanomedicine targeting amino acid metabolism for anti-tumor therapy
    Cui Pang, Xueru Song, Yizhou Luo, Huiyu Li, Wenqi Guo, Wanyi Liu, Hui Feng, Yizhang Wu, Xiaoyuan Chu, Zengjie Lei · 2025 · Journal of Nanoparticle Research
60. Revealing the landscape of targeting mitochondrial functions and behaviors to overcome cancer chemoresistance
    Haoyan Zhang, Sicheng Wang, Peng Wu, Zanmin Hu, Yani Chen, Yupeng Guan, Jun Pang · 2025 · Journal of the National Cancer Center
61. EZH2 Inhibition Induces a Metabolic Stress Response Sensitizing TNBC to Glutaminase Targeting
    Lucas Porras, Marina Fukano, Ann-Sophie Gironne, Elise Quadri, Gabriel Alzial, Hugo Philippeau, Yousef Aleassa, Anie Monast, Faustine Gorse, Myriame Saint-Arnaud et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
62. Additional file 1 of Integrative study of EZH2 mutational status, copy number, protein expression and H3K27 trimethylation in AML/MDS patients
    Julia Stomper, Ruth Meier, Tobias Ma, Pfeifer, Dietmar, Gabriele Ihorst, Nadja Blagitko‐Dorfs, Gabriele Greve, Dennis Zimmer, Platzbecker, Uwe, Anne Hagemeijer et al. · 2021 · Figshare
63. Additional file 2 of Integrative study of EZH2 mutational status, copy number, protein expression and H3K27 trimethylation in AML/MDS patients
    Julia Stomper, Ruth Meier, Tobias Ma, Pfeifer, Dietmar, Gabriele Ihorst, Nadja Blagitko‐Dorfs, Gabriele Greve, Dennis Zimmer, Platzbecker, Uwe, Anne Hagemeijer et al. · 2021 · Figshare
64. The BCAA metabolism-related gene BCAT1 promotes the progression of bladder urothelial carcinoma through the PI3K/AKT/mTOR signalling pathway
    Shiyong Xin, Guanyu Li, Le Zhao, Junjie Su, Ruixin Li, Wang Qin, Z. Zhang, Chu Wang, Yingao Zhu, Liming Feng et al. · 2026 · Functional & Integrative Genomics
65. L'autophagie, cible thérapeutique potentielle dans les néoplasies myéloprolifératives JAK2V617F
    Charly Courdy · 2022 · theses.fr (ABES)
66. Modeling Chronic Myelomonocytic Leukemia with the Aim of Identifying Novel Therapeutic Targets
    Dana Alawieh · 2025 · theses.fr (ABES)
67. BCAA catabolism mediates POU2AF1 propionylation to enhance T-ALL development
    Sijia Dan, Y J Xu, Li Xie, Xiaoxiao He, Haotian Liu, Lu Zhao, Liyuan Cao, Bo Qu, You Lü, Chiqi Chen et al. · 2026 · Cellular Oncology
68. Myeloid Malignancies Beyond the Cell: Targeting the Tumour Microenvironment with Next-Generation Immunotherapies
    Niloofar Amirian, Anya Megan Squires, Lauretta Azanabor, Claire A. Walker, Matthew J. Simmonds, Ciro Roberto Rinaldi · 2026 · Cancers
69. EZH2 inactivation drives MAPK-dependent vulnerability to MEK inhibition in RAS-mutant CMML
    Eva Gruden, Bianca Perfler, Akshaya Kailasnathan, Panagiota Chaida, KARIN LIND, Marie-Christina Mayer, Johannes Foßelteder, Melanie Kienzl, Sayantanee Dutta, Sonja Wurm et al. · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
70. ACAD8-mediated valine catabolism inhibits mTOR signaling to suppress lipid accumulation and progression of clear cell renal cell carcinoma
    Runkun Fan, Zirui Dong, Weisong Wu, Yujie Jia, Hourui Tan, Qi Wang, Xiaoping Zhang · 2026 · Translational Oncology
71. Exploiting an epigenetic resistance mechanism to PI3-kinase inhibition in leukemic stem cells
    Shira G. Glushakow-Smith, Imit Kaur, Simone Sidoli, Shayda Hemmati, Ellen Angeles, Taneisha Sinclair, Samarpana Chakraborty, Aaliyah Battle, Kristina Ames, Swathi-Rao Narayanagari et al. · 2026 · Leukemia
72. EZH2-dependent phenotypic plasticity reveals TTP-associated and mTORC1 therapeutic vulnerabilities in lethal prostate cancer
    Beatriz German, Katherine L. Morel, Teia Noel, Nadia Boufaied, Deborah L. Burkhart, Sujun Chen, Felipe Dezem, Xintao Qiu, Henry W. Long, Kun-Lin Ho et al. · 2026 · Cell Reports Medicine
73. Inactivation of the polycomb repressive complex 2 (PRC2) in osteoblasts increases post-natal trabecular bone mass and mechanical bone strength
    Amel Dudakovic, Sofía Jerez, Christopher R. Paradise, M. Lizeth Galvan, Eva Kubrova, Oksana Pichurin, Padmini J. Deosthale, Gary S. Stein, Roman Thaler, Lilian I. Plotkin et al. · 2026 · Bone